Clinical Research Directory
Browse clinical research sites, groups, and studies.
Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis
Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd.
Summary
This is a Phase IIb, long term extension study to evaluate the safety and efficacy of HB0034 in adult subjects with generalized pustular psoriasis (GPP).
Official title: A Phase IIb, Long-Term Extension Study to Evaluate the Safety and Efficacy of HB0034 in the Treatment of Adult Subjects With Generalized Pustular Psoriasis
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
33
Start Date
2024-09-02
Completion Date
2026-06-30
Last Updated
2025-02-14
Healthy Volunteers
No
Conditions
Interventions
HB0034
300mg, i.v. Q4W
Locations (3)
Peking University People's Hospital (PKUPH)
Beijing, China
Peking University People's Hospital
Beijing, China
The Second affiliated Hospital zhejiang University School of Medicine
Hangzhou, China